Does Sunitinib-Induced Hypothyroidism Play a Role in the Activity of Sunitinib in Metastatic Renal Cell Carcinoma
Chemotherapy, 06/29/2012
Clinical Article
Sella A et al. – Hypothyroidism that develops in metastatic renal cell carcinoma (mRCC) patients treated with sunitinib is associated with a trend toward prolonged PFS and survival, with a similar clinical benefit rate.



